Results 211 to 220 of about 45,745 (258)
Quantifying the Impact of Ocrelizumab on Paramagnetic Rim Lesions in Multiple Sclerosis
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Paramagnetic rim lesions (PRLs) are a subset of chronic active multiple sclerosis (MS) lesions marked by iron‐laden microglia and macrophages. Ocrelizumab, a monoclonal antibody targeting CD20+ B cells, suppresses acute MS activity, but its effect on PRLs remains unclear. In a longitudinal study of 29 ocrelizumab‐treated patients with at least
Kimberly H. Markowitz +9 more
wiley +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies
Expert Opinion on Biological Therapy, 2006Most of the existing therapeutic antibodies that have been licensed and developed as medical agents are of the human IgG1 isotype, the molecular weight of which is approximately 150 kDa. Human IgG1 is a glycoprotein bearing two N-linked biantennary complex-type oligosaccharides bound to the antibody constant region (Fc), in which the majority of the ...
Mitsuo, Satoh +2 more
openaire +4 more sources
Designing antibodies as therapeutics
Cell, 2022Antibody therapeutics are a large and rapidly expanding drug class providing major health benefits. We provide a snapshot of current antibody therapeutics including their formats, common targets, therapeutic areas, and routes of administration. Our focus is on selected emerging directions in antibody design where progress may provide a broad benefit ...
Paul J. Carter, Arvind Rajpal
openaire +2 more sources
Current Molecular Medicine, 2004
Monoclonal antibodies had the lure of drugs very much since their first description. The ability to bind to a predetermined chemical structure stimulated the imagination of drug discoverers and developers. Nevertheless it took many years before a drug was registered which started to make good on the promise.
Bernd, Groner +2 more
openaire +2 more sources
Monoclonal antibodies had the lure of drugs very much since their first description. The ability to bind to a predetermined chemical structure stimulated the imagination of drug discoverers and developers. Nevertheless it took many years before a drug was registered which started to make good on the promise.
Bernd, Groner +2 more
openaire +2 more sources
THERAPEUTIC MONOCLONAL ANTIBODIES
Rheumatology, 1995Monoclonal antibodies have been used extensively over the last few years in clinical trials of rheumatoid arthritis (RA). Not only are they potential therapeutic agents, but they are also useful probes into the immunopathogenesis of RA. Anti-tumour necrosis factor alpha (TNF alpha) monoclonal antibodies have been shown to be clinically efficacious ...
E H, Choy, G S, Panayi, G H, Kingsley
openaire +2 more sources
Therapeutic Antibodies: An Overview
2021Polyclonal immunoglobulin (Ig) preparations have been used for several decades for treatment of primary and secondary immunodeficiencies and for treatment of some infections and intoxications. This has demonstrated the importance of Igs, also called antibodies (Abs) for prevention and elimination of infections.
openaire +2 more sources
Current Opinion in Pharmacology, 2001
The development of genetic engineering technologies has today advanced to the point where the generation of high-affinity human antibodies against therapeutic targets is not a major hurdle. Rather, it is the selection of target molecules in, for example, cancer therapy that poses a challenge. Targets that are not merely passive acceptors but those that
C A, Borrebaeck, R, Carlsson
openaire +2 more sources
The development of genetic engineering technologies has today advanced to the point where the generation of high-affinity human antibodies against therapeutic targets is not a major hurdle. Rather, it is the selection of target molecules in, for example, cancer therapy that poses a challenge. Targets that are not merely passive acceptors but those that
C A, Borrebaeck, R, Carlsson
openaire +2 more sources
Synthetic therapeutic antibodies
Nature Chemical Biology, 2006Advances in selection technologies have sped up the process of generating antibodies with exquisitely tailored characteristics. In particular, synthetic antibody libraries, in which the antigen-binding sites are entirely man-made, have come of age and now rival or even exceed the potential of natural immune repertoires. Control over both library design
Sachdev S, Sidhu, Frederic A, Fellouse
openaire +2 more sources
Antibody Therapeutics in Cancer
Science, 2013In a relatively short period of time, monoclonal antibodies have entered the mainstream of cancer therapy. Their first use was as antagonists of oncogenic receptor tyrosine kinases, but today monoclonal antibodies have emerged as long-sought vehicles for the targeted delivery of potent chemotherapeutic agents and as powerful tools to manipulate ...
Mark X, Sliwkowski, Ira, Mellman
openaire +2 more sources
Synthetic antibodies as therapeutics
Expert Opinion on Biological Therapy, 2006Synthetic antibody libraries, whose repertoires are designed, have advanced in the last decade to rival natural repertoire-based libraries. Many types of diversity design have been shown to generate highly functional libraries. Defined template and defined diversity in synthetic antibody libraries improve the process of discovering and optimizing new ...
openaire +2 more sources